Skip to main content

Szyman Catherine M.'s Form 4 filing

Edwards Lifesciences Corp (EW) · filed Jul 10, 2023

Accession no.
0001225208-23-007434
Filed
Jul 10, 2023
Trade date
Jul 7-10, 2023
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $452.6K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Szyman Catherine M.CIK 0001438538Officer (CVP, Critical Care)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 7, 2023Common StockFTax withholdingDisposed−252$90.46−$22,795.9234,813.57Direct
Jul 10, 2023Common StockMOption exerciseAcquired+5,000$36.75+$183,75039,813.57Direct
Jul 10, 2023Common StockSSaleDisposed−5,000$90.52−$452,60034,813.57Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 10, 2023Common StockMOption exerciseDisposed−5,000$0.00$062,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Read the full filing on SEC EDGAR (opens in a new tab)